Glioblastoma, IDH-Wildtype — Trials

Glioblastoma, IDH-Wildtype — Trials · CancerIndex

Clinical trials

Registered studies

303 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 76
Recruiting: 42
Ph III recruiting: 3
Growth YoY: —
Industry share: 12%
Top sponsor: Mayo Clinic
Termination share: 43.9%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (64)

clinicaltrialsPublishedShowing 101–150 of 159 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00305864	Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma	completed	Phase 1 / Phase 2	118	National Cancer Institute (NCI)NIH	1	Mar 5, 2018	clinicaltrials
NCT01753713	Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma	completed	Phase 2	33	Manmeet Ahluwalia, MDOTHER	1	Dec 12, 2017	clinicaltrials